More recently, Liao and coworkers developed a dual ALDH1A1+ALDH1A3 peptide–dendritic cell vaccine and found that it induces suppression of tumor growth by eliciting a peculiar T cell immunity that specifically targets ALDH+ melanoma cells [133]. This evidence concerns the gene ALDH1A3 and neoplasm.